starting microdose of tirzepatide Microdosing Program Microdosing Tirzepatide: Benefits, Risks, and

Treat as hypothesis-generating, not as evidence of clinical Parkinsonism prevention

History of pancreatitis: Doctors most often avoid GLP-1 agonists in people with a history of pancreatitis since GLP-1 agonists may increase the risk of fatal hemorrhagic and necrotizing pancreatitis

Managing Side Effects: Diet and Wegovy Gastrointestinal side effects are the most commonly reported adverse reactions with Wegovy, affecting a significant proportion of patients, particularly during dose escalation

It may appear in a urine test for 34 days after the last dose

As a result, compounders of tirzepatide and semaglutide face risks not only from litigation by NDA holders but also from FDA enforcement actions